Docetaxel and paclitaxel for the treatment of anthracycline-resistant metastatic breast cancer: A pharmacoeconomic model

P and T

Volumn 22, Issue 11, 1997, Pages 543-552

  Peters, B G ^a   Dunphy II, F R ^a   Hill, J J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PREDNISONE; THIOTEPA; VINBLASTINE; VINCRISTINE;

BONE MARROW SUPPRESSION; BREAST CANCER; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL PRACTICE; REVIEW;

EID: 0031392162     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)